Market Research Report Insights

The global metabolic disorder therapeutics market size is expected to reach USD 88.93 billion by 2025, according to a new report by Grand View Research, Inc. The market is anticipated to witness a CAGR of 7.56% during the estimated period. Rising incidences of diabetes, obesity, and hypercholesterolemia are expected to drive the market growth. It is estimated that by 2040, about 1 person in 11 people worldwide is likely to suffer from one of the aforementioned diseases. Researchers estimate that the prevalence of metabolic diseases like obesity and diabetes is expected to double in the coming 2 decades, mainly in U.S. and Asian and Latin American countries. This, in turn, will help boost the overall market growth in the year to come. Furthermore, with better economic stability in developing countries, demand for novel therapeutics for one-time treatment has increased. This has made major companies in the global market to invest heavily in R&D to develop innovative therapy opti...

The global fabry disease treatment market size is estimated to reach a value of USD 3.12 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 9.6% during the forecast period. Rising cohort of Fabry disease, increasing adoption of novel therapies such as chaperone treatment, and potential approval of pipeline drugs including substrate reduction therapies and enzyme replacement therapies are providing a fillip to the market. Fabry disease is a rare inherited lysosomal storage disorder caused by genetic mutation that interferes with function of alpha galactosidase enzyme. Fabry disease generally has a late onset with mild symptoms, due to which several patients are often undiagnosed. Standard of care for management of the disease is enzyme replacement therapy (ERT). Sanofi’s Fabrazyme and Shire’s Replagal are the only approved ERTs in the EU; however in the U.S., only Fabrazyme has been approved. Focus of current clinical trials is to improv...

The global hunter syndrome treatment market size is expected to reach a value of USD 1.52 billion by 2026, expanding at a CAGR of 7.1%, according to a new report by Grand View Research, Inc. High unmet needs, robust pipeline, increasing awareness about this rare disease and growing R&D activities for the development of novel therapies are expected to drive market growth over the forecast period. Hunter syndrome, also referred as mucopolysaccharidosis type II (MPS II), is a rare genetic disorder caused by the missing or malfunctioning iduronate-2-sulfatase enzyme. According to the data published by the National Institute of Neurological Disorders and Stroke, MPS II syndrome occurs in around 1 in every 100,000 to 150,000 male births. Presently, there are no approved curative therapies for the treatment of Hunter syndrome. The available treatment options such as enzyme replacement therapy (ERT) and hematopoietic stem cell transplant (HSCT) are focused on providing symptomatic r...

The global intravascular catheters market size is expected to reach USD 8.8 billion by 2025, according to a new report by Grand View Research, Inc., registering an 11.8% CAGR during the forecast period. Increasing number of surgical procedures requiring catheters, growing awareness about hospital-acquired infections, and increasing coverage of healthcare insurance are some of the factors contributing to the demand for intravascular catheters from 2019 to 2025. The market is also expected to be driven by increasing number of patients undergoing cardiovascular as well as urological procedures and rising incidents of trauma injuries. Short Peripheral Intravascular Catheters (PIVC) dominated the market with a revenue of USD 2.8 billion in 2018, on account of lower infection risk associated with these products. In addition, short PIVCs are preferred over other catheters due to their quick discharge and short dwelling time. This product segment is expected to witness lucrative CAGR betw...

The global diabetic foot ulcer treatment market size is expected to reach a value of USD 6.82 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 8.2% during the forecast period. Rising prevalence of diabetes, increasing healthcare expenses, and rapidly growing geriatric population worldwide are some of the major factors driving the diabetic foot ulcer treatment market. Diabetic foot ulcers are one of the most common foot injuries that is caused due to diabetes mellitus. Management of diabetic foot ulcers aims at fast healing and wound closure, by adopting a multidisciplinary therapeutic approach so as to avoid amputation. Among different types of treatment options available, biologics held the largest share in the diabetic foot ulcer treatment market in 2017. This can be attributed to strong revenue generated by growth factors that are prescribed worldwide for their ability to promote generation of new cells and achieve wound closure....

The global hereditary angioedema therapeutic market size is expected to reach USD 4.2 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting an 8.1% CAGR during the forecast period. Growing initiatives by international patient organizations to improve awareness about hereditary angioedema (HAE) among patients and healthcare providers is likely to be a high impact rendering driver for the market. Patient advocacy organizations affiliated to HAE International (HAEi) are focusing on campaigns through both print and social media in order to raise awareness levels for hereditary angioedema. HAEi has also introduced family testing tools for improving patient awareness levels, which is likely to help in providing accurate diagnosis and optimal medical treatment. Pharmaceutical and biotechnology companies such as CSL Limited, Pharming Group N.V., and Shire Plc. engaged in development of therapies for HAE have also lent their support and collaborated with the h...